RTW Investments, a private equity firm, led a $125m investment in Milestone Pharmaceuticals, a biopharmaceutical company. "As we continue on our mission of delivering this much needed therapeutic option to patients suffering from episodic cardiovascular conditions, it is a privilege to partner with RTW on these strategic financings, which we believe further validate the value of etripamil," Amit Hasija, Milestone CFO.